GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Equity-to-Asset

ABL Bio (XKRX:298380) Equity-to-Asset : 0.45 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. ABL Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩63,808 Mil. ABL Bio's Total Assets for the quarter that ended in Mar. 2024 was ₩140,758 Mil. Therefore, ABL Bio's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.45.

The historical rank and industry rank for ABL Bio's Equity-to-Asset or its related term are showing as below:

XKRX:298380' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.22   Med: 0.91   Max: 0.98
Current: 0.45

During the past 8 years, the highest Equity to Asset Ratio of ABL Bio was 0.98. The lowest was -4.22. And the median was 0.91.

XKRX:298380's Equity-to-Asset is ranked worse than
68.06% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs XKRX:298380: 0.45

ABL Bio Equity-to-Asset Historical Data

The historical data trend for ABL Bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Equity-to-Asset Chart

ABL Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.92 0.91 0.86 0.38 0.46

ABL Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.47 0.49 0.46 0.45

Competitive Comparison of ABL Bio's Equity-to-Asset

For the Biotechnology subindustry, ABL Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABL Bio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABL Bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where ABL Bio's Equity-to-Asset falls into.



ABL Bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

ABL Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=74079.11/160144.372
=0.46

ABL Bio's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=63807.832/140758.067
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ABL Bio  (XKRX:298380) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


ABL Bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of ABL Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


ABL Bio (XKRX:298380) Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio (XKRX:298380) Headlines

No Headlines